PMID- 28371460
OWN - NLM
STAT- MEDLINE
DCOM- 20180611
LR  - 20180821
IS  - 2059-2310 (Electronic)
IS  - 2059-2302 (Linking)
VI  - 89
IP  - 5
DP  - 2017 May
TI  - Hematopoietic stem cell transplantation and cellular therapy.
PG  - 267-277
LID - 10.1111/tan.13005 [doi]
AB  - Allogeneic stem cell transplantation is a form of immunotherapy that has 
      increased the chances of survival for patients with relapsed leukemia and high 
      risk leukemia in remission. The major obstacles are graft-vs-host disease (GVHD) 
      involving vital organs and infections. A most efficacious prophylaxis of GVHD is 
      by depleting of T cells from the graft. However, problems of T-depleted 
      transplants are rejection, slow recovery of the immune system and high incidence 
      of relapse of leukemia and myeloma. The major problem of allogeneic 
      transplantation is the separation of a graft-vs-leukemia (GVL) effect from GVHD. 
      This review will summarize the factors influencing GVHD, ways to exploit rapid 
      advances in our knowledge of histocompatibility, chimerism and tolerance for 
      fostering GVL over GVHD, and in particular the use of cellular therapies 
      including donor lymphocyte infusions for disease control.
CI  - (c) 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Kolb, H-J
AU  - Kolb HJ
AD  - Helmholtz Zentrum Muenchen, Muenchen, Germany.
AD  - Ludwig Maximilians Universitaet Muenchen, Muenchen, Germany.
AD  - Klinikum Muenchen Schwabing Muenchen, Muenchen, Germany.
AD  - Department PediatricsTechnische Unoiversitaet Muenchen, Muenchen, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - HLA
JT  - HLA
JID - 101675570
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Animals
MH  - Cell- and Tissue-Based Therapy/methods
MH  - Gene Expression
MH  - Graft vs Host Disease/genetics/immunology/pathology/*prevention & control
MH  - *Graft vs Leukemia Effect
MH  - HLA Antigens/genetics/immunology
MH  - Haplotypes
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Histocompatibility Testing
MH  - Humans
MH  - *Immune Tolerance
MH  - Leukemia/genetics/immunology/pathology/*therapy
MH  - Lymphocyte Depletion
MH  - Recurrence
MH  - T-Lymphocytes/cytology/immunology/*transplantation
MH  - Transplantation Chimera
MH  - Transplantation, Homologous
OTO - NOTNLM
OT  - allogeneic hematologic stem cell transplantation
OT  - leukemia
OT  - post-transplant relapse
EDAT- 2017/04/04 06:00
MHDA- 2018/06/12 06:00
CRDT- 2017/04/04 06:00
PHST- 2017/02/16 00:00 [received]
PHST- 2017/02/16 00:00 [accepted]
PHST- 2017/04/04 06:00 [entrez]
PHST- 2017/04/04 06:00 [pubmed]
PHST- 2018/06/12 06:00 [medline]
AID - 10.1111/tan.13005 [doi]
PST - ppublish
SO  - HLA. 2017 May;89(5):267-277. doi: 10.1111/tan.13005.